Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

被引:5
作者
Latinovic, Olga [1 ,2 ]
Schneider, Kate [1 ,2 ]
Szmacinski, Henryk [3 ]
Lakowicz, Joseph R. [3 ]
Heredia, Alonso [1 ,4 ]
Redfield, Robert R. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
HIV-1; CCR5; antagonist; Maraviroc; Fusion protein; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; CHEMOKINE; TYPE-1; EXPRESSION; ENTRY; ANTIBODY; CELLS; CD4; INFECTIONS;
D O I
10.1016/j.antiviral.2014.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies inhibit HIV-1 infection, suggesting a need for more potent reagents. Here we evaluated full length single chain (FLSC) IgG1, a novel IgG-CD4-gp12(BAL) fusion protein with several characteristics that make it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC, the parental molecule. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 synergizes with Maraviroc (MVC), the only licensed CCR5 antagonist. In this study, we used both microscopy and functional assays to address the mechanistic aspects of the interactions of FLSC IgG1 and MVC in the context of CCR5 conformational changes and viral infection. We used a novel stochastic optical reconstruction microscopy (STORM), based on high resolution localization of photoswitchable dyes to visualize direct contacts between FLSC IgG1 and CCR5. We compared viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers and showed FLSC IgG1 to be the most potent. We also showed that lower CCR5 surface densities in HIV-1 infected primary cells result in lower FLSC IgG1 EC50 values. In addition, CCR5 binding by FLSC IgG1, but not CCR5 Ab 2D7, was significantly increased when cells were treated with MVC, suggesting MVC allosterically increases exposure of the FLSC IgG1 binding site. These data have implications for future antiviral therapy development. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 90
页数:11
相关论文
共 50 条
[31]   Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 [J].
Lisi, Lucia ;
Tramutola, Antonella ;
De Luca, Andrea ;
Navarra, Pierluigi ;
Dello Russo, Cinzia .
JOURNAL OF NEUROCHEMISTRY, 2012, 120 (01) :106-114
[32]   HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism [J].
Roche, Michael ;
Jakobsen, Martin R. ;
Sterjovski, Jasminka ;
Ellett, Anne ;
Posta, Filippo ;
Lee, Benhur ;
Jubb, Becky ;
Westby, Mike ;
Lewin, Sharon R. ;
Ramsland, Paul A. ;
Churchill, Melissa J. ;
Gorry, Paul R. .
JOURNAL OF VIROLOGY, 2011, 85 (09) :4330-4342
[33]   Study on CCR5 analogs and affinity peptides [J].
Wu, Yingping ;
Deng, Riqiang ;
Wu, Wenyan .
PROTEIN ENGINEERING DESIGN & SELECTION, 2012, 25 (03) :97-105
[34]   THE ROLE OF CCR5 IN HCV INFECTION [J].
Coenen, Martin ;
Nattermann, Jacob .
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (03) :97-101
[35]   The chemokine receptor, CCR5 [J].
Mueller, A ;
Strange, PG .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (01) :35-38
[36]   Multiple CCR5 Conformations on the Cell Surface Are Used Differentially by Human Immunodeficiency Viruses Resistant or Sensitive to CCR5 Inhibitors [J].
Berro, Reem ;
Klasse, Per Johan ;
Lascano, Danny ;
Flegler, Ayanna ;
Nagashima, Kirsten A. ;
Sanders, Rogier W. ;
Sakmar, Thomas P. ;
Hope, Thomas J. ;
Moore, John P. .
JOURNAL OF VIROLOGY, 2011, 85 (16) :8227-8240
[37]   Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naive Patients [J].
Marier, Jean-Francois ;
Trinh, MyMy ;
Leng Hong Pheng ;
Palleja, Sandra M. ;
Martin, David E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (06) :2768-2774
[38]   BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate [J].
Cherney, Robert J. ;
Anjanappa, Prakash ;
Selvakumar, Kumaravel ;
Batt, Douglas G. ;
Brown, Gregory D. ;
Rose, Anne, V ;
Vuppugalla, Ragini ;
Chen, Jing ;
Pang, Jian ;
Xu, Songmei ;
Yarde, Melissa ;
Tebben, Andrew J. ;
Paidi, Venkatram Reddy ;
Cvijic, Mary Ellen ;
Mathur, Arvind ;
Barrish, Joel C. ;
Mandlekar, Sandhya ;
Zhao, Qihong ;
Carter, Percy H. .
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (11) :1753-1758
[39]   CCR5 inhibitors in HIV-1 therapy [J].
Dorr, Patrick ;
Perros, Manos .
EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) :1345-1361
[40]   Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate [J].
Henrich, Timothy J. ;
Tsibris, Athe M. N. ;
Lewine, Nicolas R. P. ;
Konstantinidis, Ioannis ;
Leopold, Kay E. ;
Sagar, Manish ;
Kuritzkes, Daniel R. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (04) :420-427